Published in Ann Oncol on October 29, 2009
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica (2014) 0.84
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer (2013) 0.83
The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica (2014) 0.82
Cell of origin of transformed follicular lymphoma. Blood (2015) 0.81
Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res (2014) 0.79
Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma. Haematologica (2014) 0.78
Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One (2016) 0.75
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med (1993) 17.71
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Follicular lymphoma international prognostic index. Blood (2004) 7.20
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell (2007) 3.81
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood (2000) 3.13
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood (2005) 2.69
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
Improved survival of follicular lymphoma patients in the United States. J Clin Oncol (2005) 2.46
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood (2006) 2.40
New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol (2005) 2.40
Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol (2006) 2.39
Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol (2001) 1.96
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol (2007) 1.70
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (2006) 1.60
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res (2007) 1.35
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica (2008) 1.31
CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood (2007) 1.28
Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma (2007) 0.97
MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica (2007) 0.91
Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol (2005) 0.83
The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression. Cancer Cell (2007) 0.82
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet (2001) 3.38
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol (1990) 3.14
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Sequence analysis using logic regression. Genet Epidemiol (2001) 2.69
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem (2001) 2.67
T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med (1988) 2.63
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47
The role of adenosine 3':5'-cyclic monophosphate in the regulation of insulin release by isolated rat islets of Langerhans. Biochem J (1971) 2.41
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Evaluation and management of chylous ascites. Ann Intern Med (1982) 2.26
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
Molecular mechanisms of cytochrome c biogenesis: three distinct systems. Mol Microbiol (1998) 2.15
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Doctors divided: AIDS and the physicians at San Francisco General. CMAJ (1988) 2.10
A nonsense mutation (W9X) in CRYAA causes autosomal recessive cataract in an inbred Jewish Persian family. Invest Ophthalmol Vis Sci (2000) 2.10
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Surviving a crash landing: a software review. CMAJ (1990) 2.02
Limitations of sniff nasal pressure as an outcome measurement in amyotrophic lateral sclerosis patients in a clinical trial. Respiration (2012) 2.02
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Fourteen internal transcribed spacers in the circular ribosomal DNA of Euglena gracilis. J Mol Biol (1990) 2.00
Long-term follow-up after partial removal of a solitary kidney. N Engl J Med (1991) 1.99
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment. Exp Hematol (1998) 1.96
T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol (1991) 1.95
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
When considering attacks against the National Breast Screening Study, consider the sources. CMAJ (1993) 1.91
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
Enzyme immunohistochemistry: technical aspects. Semin Diagn Pathol (1984) 1.83
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
Imaging and treatment of B-cell lymphoma. J Nucl Med (1990) 1.68
Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell (1994) 1.67
Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat Genet (1999) 1.65
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol (1993) 1.63
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood (1987) 1.63
Intrathymic signalling in immature CD4+CD8+ thymocytes results in tyrosine phosphorylation of the T-cell receptor zeta chain. Nature (1989) 1.62
Hickman catheter infections in patients with malignancies. Medicine (Baltimore) (1984) 1.61
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 1.60
Human neoplasm pH and response to radiation therapy: P-31 MR spectroscopy studies in situ. Radiology (1989) 1.59
Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol (2000) 1.59
Elbow arthroscopy: a new technique. Arthroscopy (1989) 1.57
Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation (2001) 1.56
The news on the street: prescription drugs on the black market. CMAJ (1998) 1.56
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood (2001) 1.54
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood (1981) 1.52
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
The NDP does an abrupt about-face on user fees. CMAJ (1993) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol (1998) 1.51
Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol (2001) 1.49
The use of rectal temperature to monitor heat stroke. Mo Med (1992) 1.49
Successful treatment of Rocky Mountain 'spotless' fever. West J Med (1984) 1.48
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol (1998) 1.48
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Rheumatoid arthritis complicated by infection with the human immunodeficiency virus and the development of Sjögren's syndrome. Arthritis Rheum (1989) 1.44
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care (1999) 1.43
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma (1985) 1.43
Bile secretory apparatus: evidence for a vesicular transport mechanism for proteins in the rat, using horseradish peroxidase and [125I]insulin. Gastroenterology (1980) 1.42
Chronic-pain patients must cope with chronic lack of physician understanding. CMAJ (1991) 1.41
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol (1986) 1.40
Aortic valvoplasty for traumatic aortic insufficiency: a 2-year follow-up. Ann Thorac Surg (1990) 1.40
UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia (2008) 1.39
Wegener's granulomatosis. Immunomicroscopic and ultrastructural study of four cases. Arch Pathol Lab Med (1990) 1.39
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma (1998) 1.39
About that fee increase .... CMAJ (1992) 1.39
Infant Airtraq for adult bougie placement. Anaesthesia (2014) 1.39
Absence of Epstein-Barr virus in lymphomatoid papulosis. An immunohistochemical and in situ hybridization study. Arch Dermatol (1996) 1.38
The residency lottery. CMAJ (1993) 1.38
Professional courtesy: my colleagues will no longer be my brothers. Can Med Assoc J (1985) 1.38
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood (1994) 1.38
Why aren't we using physician assistants? CMAJ (1993) 1.37
A gene causing autosomal recessive cataract maps to the short arm of chromosome 3. Isr Med Assoc J (2001) 1.37
Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res (1998) 1.36
Qualitative differences in the lymphocyte phytohemagglutinin (PHA) response between the bone marrow and other lymphoid organs. Cell Immunol (1977) 1.35
The human T-cell leukemia-lymphoma virus in the southeastern United States. JAMA (1983) 1.34
Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol (1993) 1.32
Interaction between the components of the interferon gamma receptor complex. J Biol Chem (1995) 1.32